Cloudy vision, muted colors, difficulty driving – cataracts can have a major impact on someone’s life. More than 20 million people in the U.S. over the age of 40 have cataracts.1 Vision impairment due to cataracts is a problem many of us have and many more of us will experience. Currently more than four million cataract surgeries are performed each year in the U.S., and with the aging population, that number is expected to increase by 16% in five years.2,3
There is new hope for cataract sufferers – not only to remove their cataracts — but to restore vision – sometimes resulting in better vision than they have ever had.
The recent, highly anticipated FDA approval of the Alcon AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL) means eye doctors in the U.S. are now able to implant the first and only advanced trifocal lens that makes 20/20 vision at near, intermediate and distance possible, substantially reducing the need for glasses.4,5 With Americans living longer, more active lives and being more optimistic about their future, PanOptix technology is available at an opportune time.
Robert Cionni, M.D., a world-renowned expert in cataract surgery and a lead PanOptix clinical trial investigator, and patient Barbara Badger joined me to share more.
